Ethanol (DB00898): A Comprehensive Pharmacological, Toxicological, and Regulatory Monograph

I. Introduction and Compound Identification

Introduction

Ethanol, a simple two-carbon alcohol, holds a uniquely paradoxical position in science, medicine, and society. It is simultaneously a small molecule drug with specific, approved therapeutic applications, a widely consumed psychoactive substance with profound public health consequences, and a fundamental chemical feedstock indispensable to industry and laboratory practice. This monograph provides a definitive, evidence-based analysis of ethanol, reconciling its disparate identities through a rigorous examination of its pharmacology, toxicology, clinical utility, and the multifaceted regulatory frameworks that govern its use. A central theme of this report is the critical importance of context—dose, chronicity of exposure, genetic predisposition, and intended use—in defining ethanol's effects. The molecule's regulation is a prime example of this complexity, with distinct government bodies, such as the U.S. Food and Drug Administration (FDA) and the Alcohol and Tobacco Tax and Trade Bureau (TTB), exerting authority depending on whether the substance is intended for therapeutic use or human consumption as a beverage.[1] This report synthesizes a vast body of data to serve as a comprehensive reference for professionals in pharmacology, medicine, toxicology, and regulatory affairs.

Compound Identification

To establish the precise chemical entity under review, the following primary identifiers for ethanol are provided.

• Drug Name: Ethanol [2]
• DrugBank ID: DB00898 [2]
• Type: Small Molecule
• CAS Number: 64-17-5 [6]
• Synonyms: Ethanol is known by numerous synonyms, reflecting its widespread use. These include: Ethyl Alcohol, EtOH, Grain Alcohol, Absolute Alcohol, Dehydrated Alcohol, Methylcarbinol, Ethyl Hydrate, Ethyl Hydroxide, and Alcohol, USP.[8]

II. Physicochemical Properties

A detailed understanding of ethanol's physicochemical properties is fundamental to interpreting its pharmaceutical behavior, biological activity, and associated hazards. These properties dictate its formulation characteristics, its transport across biological membranes, and the necessary precautions for its safe handling and storage.

Chemical Structure and Formulae

• Molecular Formula: The empirical formula is commonly represented by the Hill notation as C2​H6​O.[8] The more descriptive chemical formula, which indicates the hydroxyl functional group, is C2​H5​OH.[9]
• Linear Formula: CH3​CH2​OH [7]
• Molecular Weight: The average molecular weight is consistently reported as 46.07 g/mol.[7] A more precise calculation based on common isotopic abundance gives a value of 46.0684 g/mol.[8]
• Chemical Identifiers:
• SMILES: CCO [7]
• InChI: 1S/C2H6O/c1-2-3/h3H,2H2,1H3 [7]
• InChIKey: LFQSCWFLJHTTHZ-UHFFFAOYSA-N [7]
• EC Number: 200-578-6 [7]
• Beilstein/REAXYS: 1718733 [7]

Physical Properties

Ethanol is a clear, colorless, and volatile liquid with a characteristic odor.[14] Its key physical constants are summarized in Table 1. It is hygroscopic and fully miscible with water, a property crucial for its role as a solvent in aqueous pharmaceutical preparations and its rapid distribution throughout the body's aqueous compartments.[6] Pure ethanol is chemically neutral, with a pH of approximately 7; a 10 g/L aqueous solution also exhibits a neutral pH of 7.0 at 20 °C.[6]

The combination of several physical properties underpins the significant safety hazards associated with ethanol. Its flash point, the lowest temperature at which its vapors can ignite, is approximately 13-14 °C, which is well below standard room temperature.[7] This means that an open container of ethanol at room temperature is constantly producing a flammable vapor-air mixture.[17] Compounding this risk is the fact that ethanol vapor is about 1.6 times denser than air.[7] Consequently, these flammable vapors do not rise and dissipate but instead sink and can travel considerable distances along floors, benchtops, or within trenches to find a distant ignition source, such as a spark from electrical equipment or an open flame.[16] The wide explosive range, cited as 3.3% to 19% or 3.1% to 27.7% by volume in air, indicates that a flammable mixture can form under a broad range of conditions, making ignition more likely than for substances with narrower flammable limits.[9] Together, these properties create a synergistic and often underestimated fire and explosion hazard, necessitating stringent control measures in laboratory and industrial settings.

Table 1: Key Physicochemical Properties of Ethanol (CAS 64-17-5)

Property	Value	Source(s)
Appearance	Clear, colorless liquid	14
Melting Point	-114 °C to -114.5 °C	7
Boiling Point	78 °C to 78.3 °C (at 1013 hPa)	7
Density	0.789 g/L to 0.79 g/cm³ (at 20 °C)	6
Vapor Pressure	44.6 mmHg (at 20 °C) / 57.26 hPa (at 19.6 °C)	7
Vapor Density	1.59 (vs. air)	7
Flash Point	13 °C to 14 °C	7
Autoignition Temperature	363 °C to 425 °C	7
Explosive Limits (in air)	3.1% – 27.7% (v/v)	9
Solubility in Water	Fully miscible	6
pH (10 g/L in H2​O)	7.0 (at 20 °C)	9
Refractive Index (n20/D)	1.3600	7

Reactivity and Stability

Ethanol is a highly flammable substance.[6] Its chemical stability is generally good under standard conditions, but it can react vigorously, violently, or even explosively with strong oxidizing agents such as nitric acid or bleach.[10] It also reacts with acid hydrides and acid chlorides.[10] Contact with alkali metals (e.g., sodium) or platinum can liberate flammable hydrogen gas, presenting an additional fire hazard.[10] Common laboratory materials to be kept separate from ethanol include strong acids, strong bases, and various specific reactive chemicals like potassium dioxide and bromine pentafluoride.[18] Upon combustion, it decomposes to form carbon oxides (

CO, CO2​) and other acrid fumes.[18]

III. Comprehensive Pharmacological Profile

Ethanol exerts complex, dose-dependent effects on the human body, primarily through its actions as a central nervous system (CNS) depressant. Its pharmacology is characterized by pleiotropic interactions with numerous molecular targets and a well-defined metabolic pathway that is both a source of toxicity and a hub for drug interactions.

A. Pharmacodynamics: Mechanism of Action

Ethanol does not bind to a single, specific receptor but rather modulates the function of a wide array of membrane-bound proteins, particularly neurotransmitter-gated ion channels.[14] This widespread action accounts for its diverse physiological effects, which range from anxiolysis and euphoria at low doses to sedation, motor incoordination, cognitive impairment, and general anesthesia at progressively higher doses.[19]

The primary molecular targets of ethanol are central to the balance of excitation and inhibition in the CNS.

• GABA-A Receptors: Ethanol is a positive allosteric modulator of gamma-aminobutyric acid type A (GABAA​) receptors, particularly those containing delta (δ) subunits.[19] It enhances the influx of chloride ions mediated by the brain's primary inhibitory neurotransmitter, GABA, leading to hyperpolarization of the neuron and reduced excitability. This action is the principal mechanism behind ethanol's sedative, anxiolytic, and motor-impairing effects.[14]
• NMDA Receptors: Concurrently, ethanol acts as a negative allosteric modulator of N-methyl-D-aspartate (NMDA) receptors, a key subtype of ionotropic glutamate receptors.[19] By inhibiting the function of the brain's primary excitatory neurotransmitter, glutamate, ethanol further contributes to its CNS depressant effects. This inhibition is strongly linked to the cognitive deficits, amnesia ("blackouts"), and, at very high concentrations, the anesthetic properties of ethanol.[14]
• Other Receptors and Channels: Ethanol also modulates a host of other targets, though the pharmacological significance at typical recreational doses is less clear for some. These actions include positive modulation of inhibitory glycine receptors and certain nicotinic acetylcholine and serotonin (5−HT3​) receptors, and negative modulation of excitatory AMPA and kainate receptors.[14] Furthermore, it inhibits voltage-gated L-type calcium channels and opens G-protein-activated inwardly rectifying potassium (GIRK) channels, both of which contribute to reduced neuronal activity.[14]

A critical secondary effect of these primary actions is an increase in dopamine release in the mesolimbic pathway, the brain's core reward circuit.[19] This dopaminergic activity is not a direct action but a downstream consequence of ethanol's modulation of GABAergic and glutamatergic inputs. It is this effect that mediates the pleasurable and reinforcing properties of ethanol, driving its potential for abuse and addiction.[20]

Table 2: Summary of Ethanol's Key Molecular Targets and Actions

Target	Action	Primary Clinical/Physiological Effect	Source(s)
GABA-A Receptor	Positive Allosteric Modulator	Sedation, anxiolysis, motor incoordination	14
NMDA Receptor	Negative Allosteric Modulator	Cognitive impairment, amnesia, anesthesia	14
Glycine Receptor	Positive Allosteric Modulator	Sedation, CNS depression	14
Serotonin 5-HT3 Receptor	Positive Allosteric Modulator	Nausea/vomiting modulation, reward	19
Nicotinic Acetylcholine Receptor	Positive Allosteric Modulator	Contributes to reward and cognitive effects	19
L-type Calcium Channels	Channel Blocker	Reduced neurotransmitter release	14
GIRK Channels	Channel Opener	Neuronal hyperpolarization, reduced excitability	19
Mesolimbic Pathway	Increased Dopamine Release (Secondary)	Euphoria, reinforcement, addiction potential	19

B. Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The time course of ethanol's effects is governed by its ADME profile. As a small, water-soluble molecule, it is absorbed and distributed rapidly and extensively.

• Absorption: Following oral ingestion, ethanol is rapidly absorbed from the stomach and small intestine into the bloodstream.[14] The onset of action is swift, with peak blood concentrations typically achieved within 30 to 90 minutes.[19] The rate of absorption is influenced by factors such as the presence of food in the stomach, which slows absorption, and the concentration of the beverage. On an empty stomach, peak levels can be reached in as little as 30 minutes.[19] Oral bioavailability is high, generally exceeding 80%.[19]
• Distribution: Ethanol is highly water-soluble and has low plasma protein binding, allowing it to diffuse passively and distribute throughout the body's total water content.[19] It readily crosses the blood-brain barrier to exert its effects on the CNS and also crosses the placenta, leading to fetal exposure.[14]
• Metabolism: The liver is the primary site of ethanol metabolism, accounting for the elimination of 90% or more of an ingested dose.[19] There are two main hepatic pathways:

1. Alcohol Dehydrogenase (ADH) Pathway: This is the principal, constitutively active pathway. In the cytosol of hepatocytes, the enzyme alcohol dehydrogenase (ADH) oxidizes ethanol to acetaldehyde.[11] This reaction follows zero-order kinetics at concentrations achieved with moderate drinking, meaning a constant amount of ethanol is metabolized per unit of time.
2. Microsomal Ethanol-Oxidizing System (MEOS): This secondary pathway, located in the endoplasmic reticulum, utilizes the cytochrome P450 enzyme CYP2E1.[19] The MEOS pathway is inducible; its activity significantly increases with chronic, heavy alcohol consumption. This induction is a key mechanism behind the development of metabolic tolerance, where a chronic user must consume more alcohol to achieve the same effect.[21] This pathway is also a critical nexus for drug-drug interactions, as acute ethanol intake can competitively inhibit CYP2E1, while chronic intake induces it. This bimodal effect can have opposite consequences for other drugs metabolized by the same enzyme: acute use can increase their toxicity, while chronic use can decrease their efficacy.[20]

• Metabolites and Toxicity: The intermediate metabolite, acetaldehyde, is highly reactive and significantly more toxic than ethanol itself.[11] It is a known carcinogen and is responsible for many of the unpleasant symptoms of intoxication and hangover, as well as many of the long-term health hazards of alcohol consumption, including liver damage.[11] Acetaldehyde is subsequently oxidized to non-toxic acetic acid (acetate) by aldehyde dehydrogenase (ALDH), primarily in the mitochondria.[21] Genetic polymorphisms in the ALDH2 gene, common in individuals of East Asian descent, result in a less active enzyme. This leads to the accumulation of acetaldehyde after drinking, causing the characteristic alcohol flush reaction, tachycardia, and nausea, and conferring a higher risk of esophageal cancer but a lower risk of alcoholism.[11] This provides a clear example of how pharmacokinetic variability directly drives a distinct toxicological and behavioral phenotype. Minor metabolic pathways produce ethyl glucuronide and ethyl sulfate, which are useful as long-term biomarkers of alcohol consumption.[19]
• Excretion: While the vast majority of ethanol is eliminated via metabolism, a small but consistent fraction (5-10%) is excreted unchanged through the kidneys (urine), lungs (breath), and skin (sweat).[19] The relatively stable ratio of ethanol concentration in blood to that in expired air forms the scientific basis for breathalyzer testing.[19]

Table 3: Key Pharmacokinetic Parameters of Ethanol

Parameter	Value / Description	Source(s)
Bioavailability	>80% (Oral)	19
Onset of Action	Rapid; peak concentrations in 30-90 minutes	19
Duration of Action	6-16 hours (detectable levels)	19
Metabolism	>90% Hepatic	19
Metabolic Pathways	1. Alcohol Dehydrogenase (ADH) (Primary) 2. Microsomal Ethanol-Oxidizing System (MEOS/CYP2E1) (Inducible)	19
Primary Metabolites	Acetaldehyde (toxic), Acetic Acid, Acetyl-CoA	19
Biomarker Metabolites	Ethyl Glucuronide, Ethyl Sulfate	19
Route of Elimination	>90% via metabolism; 5-10% excreted unchanged in urine, breath, sweat	19

IV. Medical and Therapeutic Applications

Despite its reputation as a recreational substance and toxin, ethanol possesses several legitimate and important therapeutic uses. These applications leverage its specific chemical and biological properties, ranging from its function as a competitive enzyme inhibitor to its direct cytotoxic effects. It is also the subject of ongoing clinical investigation for new indications.

A. Approved and Off-Label Therapeutic Uses

• Antidote for Toxic Alcohol Poisoning: Ethanol is a well-established and life-saving antidote for poisoning by methanol and ethylene glycol.[11] Both methanol and ethylene glycol are metabolized by the same primary enzyme as ethanol, alcohol dehydrogenase (ADH), into highly toxic metabolites—formaldehyde and formic acid from methanol, and glycolic acid and oxalic acid from ethylene glycol.[21] Ethanol has a significantly higher affinity for ADH than these other alcohols. When administered, it acts as a competitive inhibitor, saturating the enzyme and preventing the formation of the toxic metabolites, allowing the parent compounds to be excreted harmlessly.[11] While fomepizole (also an ADH inhibitor) is now often the preferred agent due to a more favorable side-effect profile, ethanol remains a critical, less expensive, and more readily available alternative, especially in resource-limited settings.[11]
• Therapeutic Neurolysis and Ablation: Dehydrated alcohol injection is employed for its cytotoxic properties in several clinical scenarios.[14] By causing cellular dehydration, protein denaturation, and vascular thrombosis, it can destroy targeted tissues.[14]
• Neurolysis: It is used for the chemical destruction of nerves or ganglia to provide relief from intractable chronic pain, particularly in patients with inoperable cancer or trigeminal neuralgia (tic douloureux) for whom surgical options are contraindicated.[14]
• Sclerotherapy/Ablation: Ethanol is injected directly into tumors, cysts, or vascular malformations to induce sclerosis and tissue necrosis. This serves as a minimally invasive alternative to surgery for conditions such as hypertrophic obstructive cardiomyopathy, hepatocellular carcinomas, symptomatic thyroid and renal cysts, and certain vascular malformations.[14]
• Catheter Patency and Prophylaxis: Ethanol solutions are used to treat fat occlusions in central venous catheters.[14] Furthermore, ethanol lock therapy (ELT), where a concentrated ethanol solution is instilled into the catheter lumen for a dwell time, is an effective strategy for sterilizing the device and preventing catheter-related bloodstream infections (CRBSIs), particularly in patients on long-term parenteral nutrition.[26]

B. Role as an Antiseptic and Disinfectant

Ethanol is a broad-spectrum antimicrobial agent with potent bactericidal, virucidal, and fungicidal properties.[11] It functions by dissolving the lipid bilayer of microbial cell membranes and denaturing essential proteins, leading to cell lysis and death.[11] It is effective against most common pathogens but not against bacterial spores.[11] Due to its efficacy and safety, ethanol is a key component of medical wipes and alcohol-based hand sanitizer (ABHS) formulations used for skin disinfection prior to injections and for routine hand hygiene in clinical settings.[11] Its importance is underscored by its inclusion on the World Health Organization's (WHO) Model List of Essential Medicines for its role as an antiseptic and disinfectant.[27]

C. Other Uses and Investigational Landscape

Beyond its primary therapeutic roles, ethanol is widely used as a pharmaceutical excipient, serving as a solvent and preservative in numerous liquid preparations, including cough syrups, elixirs, and herbal tinctures.[14]

The clinical trial landscape reveals ongoing interest in better understanding and utilizing ethanol's effects. A notable paradox exists in this research: ethanol itself is often the "investigational drug" in studies designed to understand its own abuse potential. Trials such as NCT04543942, which examines sex differences in risk for alcohol abuse, and NCT03431987, which investigates the neuroscience of impaired driving, use controlled administration of ethanol (DB00898) as a challenge agent to probe the underlying biological and behavioral mechanisms of alcohol use disorder and its consequences.[2] This contrasts with trials where ethanol is part of the condition being treated, such as a study on using baclofen for alcohol withdrawal.[28] This highlights ethanol's unique role as its own research tool.

Additionally, new therapeutic applications continue to be explored. For example, completed Phase 4 trials have investigated the use of ethanol for chemical neurolysis of the pericapsular nerve group and genicular nerves to treat chronic pain in advanced hip and knee osteoarthritis, respectively.[4] Other basic science trials are actively exploring the mechanistic links between alcohol consumption and pain perception.[29]

V. Safety, Toxicology, and Hazard Management

While ethanol has therapeutic uses, it is also a significant toxin and a hazardous chemical. A comprehensive safety assessment must consider its human toxicology, its physical hazards, and the protocols required for its safe management. The risks are often underestimated due to its familiarity as a recreational beverage, yet laboratory-grade ethanol presents a much higher hazard profile due to its concentration.[17]

A. Human Toxicology and Adverse Effects Profile

• Acute Toxicity: Overexposure to ethanol leads to a predictable cascade of CNS depression. Initial symptoms include headache, drowsiness, dizziness, nausea, vomiting, and impaired concentration and vision.[23] At higher concentrations, this progresses to unconsciousness, respiratory failure, and potentially death.[14] The acute oral lethal dose (LD50) in rats is reported in the range of 6,200 to 10,470 mg/kg, indicating moderate toxicity.[9]
• Chronic Toxicity: Long-term, excessive consumption of ethanol is associated with severe, multi-organ damage. The most prominent effects are hepatotoxicity (liver damage, from fatty liver to cirrhosis) and neurotoxicity (brain damage, including neuronal loss and cognitive decline).[14] Prolonged or repeated skin contact can cause defatting, leading to dryness, cracking, and dermatitis.[23]
• Reproductive and Developmental Toxicity: Ethanol is a potent teratogen. Exposure during pregnancy can cross the placenta and harm the developing fetus, causing a constellation of physical, behavioral, and cognitive abnormalities known as Fetal Alcohol Syndrome (FAS).[18] It is also reported to damage fertility in both males and females.[18]
• Carcinogenicity: The primary metabolite of ethanol, acetaldehyde, is classified as a known carcinogen.[11] The International Agency for Research on Cancer (IARC) classifies alcoholic beverages as a Group 1 carcinogen ("carcinogenic to humans"), directly linking chronic consumption to an increased risk of several cancers, including those of the oral cavity, pharynx, larynx, esophagus, liver, colorectum, and breast.[18]
• Irritation: Ethanol is a significant irritant. It causes serious eye irritation (classified as H319) and can irritate the skin and mucous membranes of the respiratory tract upon contact or inhalation.[7]

B. Physical and Environmental Hazards

The primary physical hazard of ethanol is its extreme flammability. It is classified as a highly flammable liquid and vapor (H225) and poses a dangerous fire hazard.[9] This risk is a function of several properties. Its low flash point of ~14 °C means it can be ignited by sparks, hot surfaces, or static discharge at ambient temperatures.[17] The vapors are heavier than air and can accumulate in low-lying areas or travel to distant ignition sources, creating a risk of flashback explosions.[16] This hazard is often insidious, as the flame of burning ethanol is a smokeless blue that can be nearly invisible in bright light.[16] Furthermore, sealed containers of ethanol can rupture or explode when exposed to the heat of a fire.[23]

Environmentally, ethanol is considered slightly hazardous to water (WGK 1).[7] A large spill into an aquatic ecosystem can lead to rapid biodegradation that consumes dissolved oxygen, potentially causing hypoxia and harming aquatic life.[16] Denatured ethanol formulations may contain other solvents that are more potent aquatic toxicants.[17]

C. Safe Handling, Storage, and Emergency Procedures

The significant hazards of ethanol necessitate strict safety protocols, particularly in settings where high concentrations are used.

• Engineering Controls: To mitigate the risk of vapor accumulation, work with significant volumes (>500 mL) should be conducted within a chemical fume hood or other well-ventilated area.[17] All electrical and ventilating equipment in areas of use must be explosion-proof.[30]
• Safe Work Practices: Open containers of ethanol must be kept far from any potential ignition sources, including open flames, hot plates, and sparking equipment.[17] Metal containers must be properly bonded and grounded during transfer to prevent static discharge.[17]
• Storage: Ethanol must be stored in a cool, dry, well-ventilated area designated for flammable liquids, away from heat and incompatible materials like oxidizers.[18] Containers must be kept tightly closed.[9] A critical and often overlooked requirement is that ethanol must not be stored in standard laboratory or domestic refrigerators. The internal components of these appliances (lights, switches, fans) can act as ignition sources for accumulated vapors, creating a high risk of explosion. Only certified explosion-proof or flammable-safe refrigerators are suitable for storing ethanol.[17]
• Personal Protective Equipment (PPE): Standard PPE includes chemical splash goggles and a face shield for eye and face protection, and impermeable gloves (e.g., Butyl or Neoprene rubber) to prevent skin contact.[7] For situations with high vapor concentrations, appropriate respiratory protection (e.g., a respirator with an organic vapor cartridge) is required.[16]
• Emergency Procedures: In case of a spill, all ignition sources must be eliminated, and the area should be ventilated. The spill should be contained with an inert absorbent material and collected for proper disposal.[16] In case of fire, alcohol-resistant foam, dry chemical, or carbon dioxide extinguishers are appropriate; water spray may be used to cool containers but may be ineffective at extinguishing the fire itself.[30] First aid for exposures involves immediate flushing of eyes or skin with water, moving to fresh air for inhalation, and seeking immediate medical attention for ingestion without inducing vomiting.[18]

VI. Drug Interaction Profile

Ethanol interacts with a vast number of medications, with over 500 known drug-drug interactions documented.[31] These interactions can be pharmacodynamic (where ethanol's effects are added to or synergize with those of another drug) or pharmacokinetic (where ethanol or the other drug alters the absorption, distribution, metabolism, or excretion of the other). The clinical consequences can range from minor to life-threatening.

A. Pharmacodynamic Interactions

These interactions occur when ethanol and another drug act on similar physiological systems, leading to an amplified effect.

• Central Nervous System Depressants: This is the most clinically significant and prevalent category of pharmacodynamic interaction. Ethanol produces additive or synergistic CNS depression when combined with a wide range of medications, leading to profound sedation, impaired psychomotor function, respiratory depression, coma, and death.[20] Key classes include:
• Benzodiazepines and Z-drugs (e.g., alprazolam, lorazepam, zolpidem) [14]
• Opioids (e.g., hydrocodone, oxycodone, fentanyl) [20]
• Barbiturates [20]
• First-generation antihistamines (e.g., diphenhydramine) [20]
• Antipsychotics and many antidepressants [22]
• Skeletal muscle relaxants (e.g., baclofen, cyclobenzaprine) [32]
• Antihypertensives and Vasodilators: Ethanol possesses vasodilatory properties, which can enhance the effects of antihypertensive medications (e.g., beta-blockers, calcium channel blockers) and other vasodilators (e.g., nitrates). This can lead to an increased risk of orthostatic hypotension, dizziness, syncope, and falls.[14]

B. Pharmacokinetic Interactions

These interactions involve the alteration of a drug's ADME profile. A critical aspect is the bimodal effect of ethanol on hepatic metabolism: acute intake inhibits enzymes, while chronic intake induces them.

• Effects of Ethanol on Other Drugs:
• Enzyme Inhibition (Acute Use): A single episode of drinking can competitively inhibit cytochrome P450 enzymes, particularly CYP2E1. This slows the metabolism of other drugs that are substrates for these enzymes, leading to higher-than-expected plasma concentrations and an increased risk of toxicity.[22]
• Enzyme Induction (Chronic Use): Long-term, heavy alcohol consumption induces the expression of CYP2E1.[21] This accelerates the metabolism of other CYP2E1 substrates, which can decrease their therapeutic efficacy. A classic example is acetaminophen, where CYP2E1 induction by chronic alcohol use shunts more of the drug down a minor pathway to form its highly toxic metabolite, NAPQI, dramatically increasing the risk of severe liver injury even at standard therapeutic doses of acetaminophen.[20]
• Effects of Other Drugs on Ethanol Metabolism:
• Disulfiram-like Reaction: Certain drugs, most notably disulfiram itself but also metronidazole and some cephalosporin antibiotics (e.g., cefotetan), inhibit the enzyme aldehyde dehydrogenase (ALDH).[21] If ethanol is consumed while these drugs are present, ALDH is blocked, causing the rapid accumulation of the toxic metabolite acetaldehyde. This results in a severe and highly unpleasant reaction characterized by intense flushing, throbbing headache, nausea, vomiting, tachycardia, and hypotension.[21]
• ADH Inhibition: Other drugs can inhibit alcohol dehydrogenase, slowing the initial step of ethanol metabolism and prolonging its intoxicating effects.[22]

C. Clinically Significant Drug-Ethanol Interactions

The sheer number of interactions precludes a full listing, but they can be categorized by severity.

• Contraindicated or Major Interactions: These combinations pose a high risk and should be avoided. Examples include acitretin (ethanol converts it to a highly persistent teratogen), disulfiram (causes severe reaction), sodium oxybate (risk of profound CNS depression), and flibanserin (risk of severe hypotension and syncope).[33]
• Serious Interactions: These combinations carry significant risk and should generally be avoided or used only with extreme caution and close monitoring. This category includes all opioids, many antidiabetic agents (increased risk of hypoglycemia), methotrexate (increased hepatotoxicity), and ketorolac and other NSAIDs (increased risk of GI bleeding).[33]
• Moderate Interactions: This is the largest group and includes many commonly prescribed medications. While the risk is less severe, caution is still warranted. Examples include statins, many antidepressants, and warfarin.[14]

Table 4: Selected Major and Moderate Drug Interactions with Ethanol

Interacting Drug/Class	Severity	Mechanism	Clinical Outcome / Recommendation	Source(s)
Opioids (e.g., Oxycodone)	Major	Pharmacodynamic: Synergistic CNS and respiratory depression.	Risk of profound sedation, respiratory depression, coma, and death. Avoid combination.	20
Benzodiazepines (e.g., Alprazolam)	Major	Pharmacodynamic: Synergistic CNS depression.	Risk of profound sedation, impaired psychomotor function. Avoid combination.	20
Disulfiram, Metronidazole	Major	Pharmacokinetic: Inhibition of aldehyde dehydrogenase (ALDH).	Causes severe disulfiram-like reaction (flushing, nausea, tachycardia). Strictly avoid ethanol.	21
Acitretin	Major	Pharmacokinetic: Ethanol promotes conversion to etretinate, a long-lasting teratogen.	Contraindicated. Women must avoid ethanol during and for 2 months after therapy.	33
Methotrexate	Serious	Pharmacokinetic/Pharmacodynamic: Increased risk of hepatotoxicity.	Avoid combination, especially with chronic ethanol use. Monitor liver function.	33
NSAIDs (e.g., Ibuprofen, Aspirin)	Moderate	Pharmacodynamic: Additive risk of gastrointestinal irritation and bleeding.	Use with caution. Advise patients of increased risk of stomach bleeding.	32
Antidiabetic Agents (e.g., Sulfonylureas, Metformin)	Serious	Pharmacodynamic: Can cause hypoglycemia. Chronic use can cause hyperglycemia. Increased risk of lactic acidosis with metformin.	Counsel patients on effects on blood glucose. Use with caution.	33
Warfarin	Moderate	Pharmacokinetic: Acute ethanol intake inhibits metabolism (↑ INR); chronic intake induces metabolism (↓ INR).	Unpredictable effects on anticoagulation. Frequent INR monitoring required if use is unavoidable.	14
Acetaminophen	Moderate	Pharmacokinetic: Chronic ethanol use induces CYP2E1, increasing formation of toxic metabolite (NAPQI).	Increased risk of severe hepatotoxicity. Limit acetaminophen dose and avoid chronic ethanol use.	20

VII. Pharmaceutical-Grade Ethanol: Manufacturing and Regulatory Landscape

Ethanol intended for medical or pharmaceutical use is subject to far more stringent standards of purity and manufacturing control than ethanol produced for fuel or industrial purposes. Its regulation is uniquely complex, determined not by the chemical itself but by its intended application.

A. Manufacturing Processes and Quality Standards

• Production and Purification: Pharmaceutical-grade ethanol, often referred to as Extra Neutral Alcohol (ENA), is typically produced through the fermentation of agricultural feedstocks like sugarcane, corn, or wheat, which yields a dilute ethanol solution.[35] This is followed by a multi-stage distillation process designed to remove water and impurities, achieving a very high concentration (e.g., 96% or >99.7%) and degree of purity.[15] While less common for food or drug use, synthetic ethanol derived from petroleum can be used if it meets the required pharmacopeial purity standards.[37]
• Quality Control and GMP: The manufacturing process must adhere to Good Manufacturing Practice (GMP) guidelines.[38] This ensures that the product is consistently produced and controlled according to quality standards appropriate for its intended use in human and veterinary medicine. A primary focus of quality control is the rigorous testing for and removal of impurities. The most critical impurity is acetaldehyde, a known carcinogen, which must be controlled to very low levels (e.g., max 0.00030 g/100 mL).[15] Other impurities such as methanol, fusel oils, and evaporation residues are also strictly limited.[15]
• Pharmacopeial Standards and Commercial Availability: To be sold as pharmaceutical grade, ethanol must meet the specifications outlined in major pharmacopeias, such as the United States Pharmacopeia (USP), European Pharmacopeia (EP), British Pharmacopeia (BP), and Japanese Pharmacopeia (JP).[38] It is commercially available from specialized suppliers (e.g., Sasma, Nedstar, Lab Alley) in various grades (e.g., GMP Grade, API Grade, USP Grade), concentrations (e.g., 70%, 95%, 96%, 99.9% anhydrous), and packaging options.[38] It can be supplied as undenatured (pure) ethanol or denatured ethanol, where other substances are added to render it unfit for consumption, thereby avoiding beverage alcohol taxes.[38] Brand names for finished drug products containing pharmaceutical-grade ethanol include topical antiseptics like Lavacol and Nozin, and intravenous solutions like Ablysinol.[5]

B. Regulatory Framework and Compliance (U.S. Focus)

The regulatory oversight of ethanol in the United States is a prime example of "regulation by intent," where the governing body and the applicable rules depend entirely on the product's final use.

• FDA Regulation of Ethanol in Drugs and Food: The FDA regulates ethanol when it is used as an active or inactive ingredient in a drug product, or as a food additive.
• 21 CFR Part 328: This key regulation governs the use of ethanol as an inactive ingredient in orally ingested over-the-counter (OTC) drug products.[42] It establishes strict, age-based limits on alcohol concentration to protect vulnerable populations, especially children. It also mandates prominent labeling of the alcohol percentage on the principal display panel.[42]
• Methanol Contamination Policy: Following a series of fatal poisonings from contaminated hand sanitizers during the COVID-19 pandemic, the FDA issued and later finalized a guidance document that applies to all pharmaceutical alcohol.[43] This policy mandates that all lots of ethanol or isopropyl alcohol used in pharmaceuticals be tested for methanol contamination. Any batch found to contain more than 200 ppm of methanol is considered adulterated, highlighting the agency's focus on supply chain integrity and prevention of economically motivated adulteration.[43]
• GRAS Status: The FDA also regulates ethanol as a food substance. It is listed as Generally Recognized As Safe (GRAS) under 21 CFR 184.1293 for specific, limited uses, such as an antimicrobial agent on pizza crusts.[1] This GRAS status for food use is distinct from its regulation as a drug ingredient.
• Multi-Agency Oversight: The regulatory landscape is fragmented. While the FDA oversees drugs and food additives [1], the Alcohol and Tobacco Tax and Trade Bureau (TTB) of the Department of the Treasury regulates the production and taxation of alcoholic beverages.[1] Furthermore, the Environmental Protection Agency (EPA) regulates bulk ethanol under the Emergency Planning and Community Right-to-Know Act (EPCRA) as a hazardous chemical requiring inventory reporting. The only exemption from EPA reporting is for ethanol that is packaged and used as an FDA-regulated food, drug, or cosmetic.[1] This creates a complex compliance environment where a single manufacturer may need to adhere to the distinct rules of the FDA, TTB, and EPA for the exact same chemical substance, depending on its stage in the supply chain and its final intended market.

Table 5: Summary of FDA Regulations for Ethanol in Over-the-Counter (OTC) Oral Drug Products (21 CFR Part 328)

Target Population	Maximum Allowable Alcohol Concentration (as an inactive ingredient)	Specific Labeling Requirements	Source(s)
Adults & Children ≥12 years	10%	Must state percentage of alcohol on principal display panel. If >5%, must include: "Consult a physician for use in children under 12 years of age."	42
Children 6 to <12 years	5%	Must state percentage of alcohol on principal display panel. If >0.5%, must include: "Consult a physician for use in children under 6 years of age."	42
Children <6 years	0.5%	Must state percentage of alcohol on principal display panel.	42
Any Product	0%	Required to be labeled "alcohol free."	42

VIII. Synthesis and Expert Recommendations

This monograph has detailed the multifaceted nature of ethanol, a simple molecule whose biological and societal impact is profoundly dictated by context. The analysis reveals a substance of duality: it is a therapeutic agent and a potent toxin, a CNS depressant whose effects are mediated by a complex interplay of actions on inhibitory and excitatory neurotransmitter systems. Its pharmacology is defined by a dose-dependent continuum of effects and a metabolic pathway that is both a source of toxicity, via the carcinogenic metabolite acetaldehyde, and a critical determinant of drug-drug interactions. The bimodal nature of these interactions—where acute use inhibits metabolism and chronic use induces it—presents a significant clinical challenge. Finally, its regulatory landscape is uniquely fragmented, governed not by the molecule's identity but by its intended use, creating a complex compliance environment.

Based on this comprehensive analysis, the following recommendations are put forth for key stakeholders.

Recommendations for Clinicians

1. Prioritize Alcohol Use Screening: Given the more than 500 documented drug-ethanol interactions, clinicians should implement routine, proactive screening for alcohol consumption patterns in all patients. This is essential for safe prescribing and for interpreting therapeutic outcomes for a vast range of common medications.
2. Provide Nuanced Interaction Counseling: Counseling should move beyond simple warnings to "avoid alcohol." Clinicians must explain the different risks associated with acute ("binge") versus chronic consumption, particularly for drugs metabolized by CYP2E1 (e.g., acetaminophen) or those with narrow therapeutic indices (e.g., warfarin).
3. Utilize Biomarkers When Necessary: In high-risk clinical scenarios, such as for patients receiving hepatotoxic drugs (methotrexate) or known teratogens affected by ethanol (acitretin), the use of sensitive biomarkers like urinary ethyl glucuronide (EtG) should be considered to verify abstinence and ensure patient safety.
4. Maintain Awareness of Therapeutic Uses: Clinicians, particularly in emergency medicine, should remain aware of ethanol's legitimate therapeutic applications, most critically its role as a readily available and effective antidote for methanol and ethylene glycol poisoning.

Recommendations for Researchers

1. Elucidate Mechanistic Contributions: While ethanol's primary molecular targets are known, further research is needed to dissect the specific contribution of each target (e.g., different GABAA​ receptor subtypes, NMDA receptors, GIRK channels) to its complex behavioral, reinforcing, and toxic effects.[19] This will enable the development of more targeted therapies for alcohol use disorder.
2. Investigate Pharmacokinetic Variability: Research should focus on the clinical impact of combined genetic and environmental factors on ethanol's pharmacokinetics. Specifically, studies are needed to model the net effect of ADH/ALDH polymorphisms co-existing with varying degrees of CYP2E1 induction on both ethanol-related organ damage and drug-drug interaction risk.
3. Optimize Therapeutic Ablation Techniques: Further clinical trials should investigate and refine the use of ethanol for therapeutic neurolysis and sclerotherapy, leveraging advanced imaging guidance (e.g., endoscopic ultrasound) to improve targeting precision, maximize efficacy, and minimize damage to surrounding healthy tissue.[4]

Recommendations for Regulators and Public Health Officials

1. Ensure Supply Chain Integrity: Regulatory agencies must maintain stringent oversight and enforcement of testing requirements for methanol contamination in the pharmaceutical alcohol supply chain. The events of the COVID-19 pandemic demonstrated that this remains a critical and persistent public health risk, particularly when supply chains are stressed.[43]
2. Enhance Public Awareness of Polysubstance Risks: Public health campaigns should specifically target the dangers of combining ethanol with other CNS depressants. Given the ongoing opioid crisis and the widespread use of benzodiazepines, clear messaging about the synergistic and potentially fatal effects of these combinations is urgently needed.
3. Evaluate Regulatory Harmonization: While respecting the distinct missions of the TTB, FDA, and EPA, these agencies should explore opportunities to harmonize reporting requirements and definitions for ethanol where feasible. This could reduce the administrative burden on manufacturers navigating the complex regulatory patchwork without compromising safety or oversight.

Works cited

1. Ethanol added to food / beverages and Tier II reporting (i.e., EPCRA Section 312) | US EPA, accessed July 29, 2025, https://www.epa.gov/epcra/ethanol-added-food-beverages-and-tier-ii-reporting-ie-epcra-section-312
2. Alcohol Abuse Completed Phase Trials for Ethanol (DB00898) | DrugBank Online, accessed July 29, 2025, https://go.drugbank.com/indications/DBCOND0030596/clinical_trials/DB00898?status=completed
3. Alcohol Drinking Unknown Status Phase Trials for Ethanol (DB00898) | DrugBank Online, accessed July 29, 2025, https://go.drugbank.com/indications/DBCOND0030623/clinical_trials/DB00898?phase=&status=unknown_status
4. Osteoarthritis (OA) Completed Phase 4 Trials for Ethanol (DB00898) | DrugBank Online, accessed July 29, 2025, https://go.drugbank.com/indications/DBCOND0056529/clinical_trials/DB00898?phase=4&status=completed
5. Ethanol - brand name list from Drugs.com, accessed July 29, 2025, https://www.drugs.com/ingredient/ethanol.html
6. www.chemicalbook.com, accessed July 29, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2362508.htm#:~:text=Chemical%20properties,-Ethanol%20is%20highly&text=Density%20of%20ethanol%20at%2068,and%20fully%20miscible%20in%20water.
7. Ethanol Sigma-Aldrich CAS No.64-17-5, accessed July 29, 2025, https://www.sigmaaldrich.com/US/en/product/sial/02891
8. Ethanol, accessed July 29, 2025, https://webbook.nist.gov/cgi/cbook.cgi?ID=64-17-5
9. Ethanol CAS 64-17-5 | 102371 - Merck, accessed July 29, 2025, https://www.merckmillipore.com/INTL/en/product/Ethanol,MDA_CHEM-102371
10. CAS Number 64-17-5 | Ethyl Alcohol - Spectrum Chemical, accessed July 29, 2025, https://www.spectrumchemical.com/cas/64-17-5
11. Ethanol - Wikipedia, accessed July 29, 2025, https://en.wikipedia.org/wiki/Ethanol
12. Ethanol API Grade | Sigma-Aldrich, accessed July 29, 2025, https://www.sigmaaldrich.com/US/en/product/mm/ark2210
13. ethyl alcohol - cfsanappsexternal.fda.gov, accessed July 29, 2025, https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=FoodSubstances&id=ETHYLALCOHOL
14. Ethanol: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 29, 2025, https://go.drugbank.com/drugs/DB00898
15. Pharmaceutical Grade Ethanol | Godavari, accessed July 29, 2025, https://www.godavaribiorefineries.com/products/alcohol/Pharamaceutical-Grade-Ethanol
16. Ethanol: Associated hazards and safety measures - Gexcon AS, accessed July 29, 2025, https://www.gexcon.com/blog/ethanol-associated-hazards-and-safety-measures/
17. Page 1 Ethanol Factsheet - Stanford Environmental Health & Safety, accessed July 29, 2025, https://ehs.stanford.edu/wp-content/uploads/19-157_Ethanol-Fact-Sheet_Final.pdf
18. Safety Data Sheet - Fisher Scientific, accessed July 29, 2025, https://www.fishersci.com/content/dam/fishersci/en_US/documents/programs/education/regulatory-documents/sds/chemicals/chemicals-e/S25309E.pdf
19. Pharmacology of ethanol - Wikipedia, accessed July 29, 2025, https://en.wikipedia.org/wiki/Pharmacology_of_ethanol
20. What is Ethanol used for? - Patsnap Synapse, accessed July 29, 2025, https://synapse.patsnap.com/article/what-is-ethanol-used-for
21. Physiology and pharmacology of alcohol: the imidazobenzodiazepine alcohol antagonist site on subtypes of GABAA receptors as an opportunity for drug development? - PMC - PubMed Central, accessed July 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2442438/
22. Drug interactions with alcohol - PubMed, accessed July 29, 2025, https://pubmed.ncbi.nlm.nih.gov/387374/
23. Inhaling Ethyl Alcohol - Hazardous Substance Fact Sheet, accessed July 29, 2025, https://www.nj.gov/health/eoh/rtkweb/documents/fs/0844.pdf
24. Alcohol (drug) - Wikipedia, accessed July 29, 2025, https://en.wikipedia.org/wiki/Alcohol_(drug)
25. www.ncbi.nlm.nih.gov, accessed July 29, 2025, https://www.ncbi.nlm.nih.gov/books/NBK556147/#:~:text=Ethanol%20is%20an%20alcohol%20that,an%20alternative%20to%20surgical%20interventions.
26. Ethanol - StatPearls - NCBI Bookshelf, accessed July 29, 2025, https://www.ncbi.nlm.nih.gov/books/NBK556147/
27. How ethanol is used in medicine - Essentica, accessed July 29, 2025, https://essentica.eu/news/about-the-industry/how-ethanol-is-used-in-medicine
28. Alcohol Withdrawl Enrolling by Invitation Phase Trials for Ethanol (DB00898) - DrugBank, accessed July 29, 2025, https://go.drugbank.com/indications/DBCOND0036373/clinical_trials/DB00898?phase=&status=enrolling_by_invitation
29. Ethanol Completed Phase 1 Trials for Pain / Behavior, Drinking / Acute Pain / Drinking, Alcohol Basic Science - DrugBank, accessed July 29, 2025, https://go.drugbank.com/drugs/DB00898/clinical_trials?conditions=DBCOND0003831%2CDBCOND0092813%2CDBCOND0109893%2CDBCOND0012160&phase=1&purpose=basic_science&status=completed
30. Ethanol - SAFETY DATA SHEET, accessed July 29, 2025, https://www.sigmaaldrich.com/IN/en/sds/sial/459836
31. Ethyl Alcohol Interactions Checker - Drugs.com, accessed July 29, 2025, https://www.drugs.com/drug-interactions/ethanol,ethyl-alcohol.html
32. Ethanol Interactions Checker - Drugs.com, accessed July 29, 2025, https://www.drugs.com/drug-interactions/ethanol.html
33. Alcohol, ethyl (ethanol) dosing, indications, interactions, adverse ..., accessed July 29, 2025, https://reference.medscape.com/drug/alcohol-ethyl-ethanol-343730
34. Drug-Alcohol Interactions: A Review of Three Therapeutic Classes - U.S. Pharmacist, accessed July 29, 2025, https://www.uspharmacist.com/article/drug-alcohol-interactions-a-review-of-three-therapeutic-classes
35. Pharma Grade ENA Spirit Production Plant - Advancebiofuel, accessed July 29, 2025, https://advancebiofuel.in/pharma-grade-ena-spirit-production-plant/
36. Pharma Grade Ethanol Plant Manufacturer & Supplier - Attomo.in, accessed July 29, 2025, https://attomo.in/services/pharma-grade-ethanol-plant/
37. CPG Sec 555.100 Alcohol; Use of Synthetic Alcohol in Foods February 1989 - FDA, accessed July 29, 2025, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-555100-alcohol-use-synthetic-alcohol-foods
38. Ethanol 96% GMP Grade | Sasma Premium Alcohol Suppliers, accessed July 29, 2025, https://sasmabv.com/products/ethanol-96-gmp-grade/
39. Ethanol Ethyl Alcohol | Lab Alley, accessed July 29, 2025, https://www.laballey.com/collections/ethanol
40. Pharmaceutical grade alcohol for medical use - Nedstar, accessed July 29, 2025, https://www.nedstar.com/industries/main-industries/pharmaceutical-alcohol
41. Ethanol grades, solvents & oleochemicals for pharmaceuticals, accessed July 29, 2025, https://www.wilmarsugar-anz.com/what-we-do/bioethanol/pharmaceutical
42. 21 CFR Part 328 -- Over-the-Counter Drug Products Intended for Oral Ingestion That Contain Alcohol - eCFR, accessed July 29, 2025, https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-328
43. Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol Guidance for Industry October 2023 - FDA, accessed July 29, 2025, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol
44. FDA guidance calls for testing all alcohol-based products for methanol - RAPS, accessed July 29, 2025, https://www.raps.org/news-and-articles/news-articles/2023/10/fda-guidance-calls-for-testing-all-alcohol-based-p
45. Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol - FDA, accessed July 29, 2025, https://www.fda.gov/media/173005/download
46. 21 CFR § 184.1293 - Ethyl alcohol. - Law.Cornell.Edu, accessed July 29, 2025, https://www.law.cornell.edu/cfr/text/21/184.1293